Gooch Jennifer L, Pèrgola Pablo E, Guler Rebecca L, Abboud Hanna E, Barnes Jeffrey L
Department of Medicine, Division of Nephrology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
J Am Soc Nephrol. 2004 Jun;15(6):1421-9. doi: 10.1097/01.asn.0000128076.91545.bb.
Calcineurin is an important signaling molecule in mesangial cells in vitro and is involved in some manifestations of diabetic nephropathy in vivo. However, calcineurin acts in a cell-specific and tissue-specific manner in the kidney, and mechanisms of specificity are unknown. Three closely related isoforms of the calcineurin A (CnA) subunit are expressed in a tissue-specific manner. This study was undertaken to determine if specificity of calcineurin action is linked to regulation of CnA isoforms in the diabetic kidney. After induction of diabetes with streptozotocin, expression of all three CnA isoforms rapidly increased, primarily in the thick ascending limb of Henle (TAL). After prolonged diabetes, increase specifically of the alpha isoform was observed in collecting ducts (CD) and in endothelial cells of glomeruli. Aquaporin 2 (AQP2), a putative substrate of calcineurin phosphatase in the kidney, is also involved in diabetic nephropathy. Co-localization of CnA isoforms with AQP2 revealed that CnA-alpha is the predominant isoform that associates with AQP2 in the diabetic kidney. Furthermore, inhibition of calcineurin with cyclosporin A (CsA) alters AQP2 localization and phosphorylation in principal cells of CD. Alterations in subcellular localization of AQP2 were parallel with CnA-alpha. Similarly, CsA treatment results in a further increase in urine output compared with diabetes alone, suggesting a functional consequence of inhibiting calcineurin-mediated regulation of AQP2. In conclusion, all three isoforms of CnA are upregulated in the diabetic kidney. Increased expression of CnA-alpha, in particular, is observed in glomeruli and CD and participates in regulation of AQP2 expression, phosphorylation, and function.
钙调神经磷酸酶是体外系膜细胞中的一种重要信号分子,且参与体内糖尿病肾病的某些表现。然而,钙调神经磷酸酶在肾脏中以细胞特异性和组织特异性方式发挥作用,其特异性机制尚不清楚。钙调神经磷酸酶A(CnA)亚基的三种密切相关的同工型以组织特异性方式表达。本研究旨在确定钙调神经磷酸酶作用的特异性是否与糖尿病肾脏中CnA同工型的调节有关。用链脲佐菌素诱导糖尿病后,所有三种CnA同工型的表达迅速增加,主要在髓袢升支粗段(TAL)。长期患糖尿病后,在集合管(CD)和肾小球内皮细胞中观察到α同工型特异性增加。水通道蛋白2(AQP2)是肾脏中钙调神经磷酸酶的一种假定底物,也参与糖尿病肾病。CnA同工型与AQP2的共定位显示,CnA-α是糖尿病肾脏中与AQP2相关的主要同工型。此外,用环孢素A(CsA)抑制钙调神经磷酸酶会改变CD主细胞中AQP2的定位和磷酸化。AQP2亚细胞定位的改变与CnA-α平行。同样,与单独患糖尿病相比,CsA治疗导致尿量进一步增加,提示抑制钙调神经磷酸酶介导的AQP2调节具有功能后果。总之,糖尿病肾脏中CnA的所有三种同工型均上调。特别是,在肾小球和CD中观察到CnA-α的表达增加,并参与AQP2表达、磷酸化和功能的调节。